Aug 23, 2023

Medtronic announces first patient treated in global collaboration with Cydar Medical

40-site pilot program across US, UK, and Europe aims to introduce cutting edge AI solutions into the clinical environment to improve patient care and efficiency

Medtronic is announcing the first patient treated in a global pilot program in collaboration with Cydar Medical. The pilot in our Aortic business spans up to 40 global sites using the latest artificial intelligence (AI) technology from Cydar Medical. Cydar’s unique technology is designed to enhance Medtronic’s unrivaled service and case support for physicians to validate long-term predictive capabilities and improve patient care. The first patient in the pilot program received endovascular treatment earlier this month in conjunction with Cydar’s Maps at Edward Hospital in Naperville, Illinois by Dr. George Pontikis.

This strategic collaboration combines Medtronic’s innovation expertise in aortic care with Cydar’s AI technology. Medtronic is the first medical device company to enter a public strategic collaboration in digital endovascular technology to advance aortic patient treatment decisions, reflecting its ongoing commitment to advancing aortic care for physicians and their patients.

“This is a significant milestone in Medtronic’s collaboration with Cydar Medical as we aim to revolutionize endovascular aortic treatment with cutting-edge, digital solutions,” said Nina Goodheart, SVP and President of the Structural Heart & Aortic business at Medtronic. “We look forward to continued progress toward our vision to provide physicians with enhanced knowledge to get the best possible outcomes for their patients.”

Cydar Maps is the first product from Cydar’s AI technology platform that transforms the way information is provided to clinicians undertaking image-guided minimally invasive surgery. Cydar Maps generates a 3D map of patient soft tissue to support and integrate pre-operative planning, intra-operative guidance, and post-operative review of endovascular minimally invasive surgery, using AI to update the map throughout the patient journey. One of the reasons Medtronic chose Cydar Medical to pilot with is because Cydar Maps has been shown in independent studies to offer a number of benefits, including halving the radiation exposure for patients and the clinical team, simplifying the clinical workflow and increasing clinician confidence, which in turn can significantly reduce procedure times1, 2, 3.

 "This is an important milestone for Cydar, to be working with Medtronic to accelerate the adoption of our AI-solution by the global endovascular community,” said Paul Mussenden, CEO of Cydar. “The goal is to provide clinicians with a more predictable and efficient way to perform minimally invasive image-guided procedures. We look forward to supporting the treatment of additional patients across the planned 40 sites and to continue the introduction of the exciting product developments we have planned over the course of the year ahead.”

Medtronic and Cydar anticipate this pilot program will be the first step in the development of predictive analytics to support procedure planning, by assessing factors such as the risk of endoleaks, sac regression probability and more.

“This cutting-edge technology empowers us with the ability to navigate complex vascular procedures with greater precision, ensuring optimal outcomes for our patients. We are honored to be a part of this innovative program and are eager to contribute to the advancement of endovascular aortic surgery,“ said George Pontikis, MD, vascular surgeon at Edward Hospital in Naperville, Illinois.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit and follow @Medtronic on Twitter and LinkedIn.


Rachel Murray
Public Relations

Ryan Weispfenning
Investor Relations



1 Shortell C, Veith Symposium New York, 2017
2 Southerland et al. Image-Based Three-Dimensional Fusion Computed Tomography Decreases Radiation Exposure, Fluoroscopy Time, and Procedure Time During Endovascular Aortic Aneurysm Repair. Journal of Vascular Surgery Abstracts e61. Volume 67, Number 6
3 Blandine et al. A prospective observational trial of fusion imaging in infrarenal aneurysms J Vasc Surg. 2018 Dec;68(6):1706-1713.e1. doi: 10.1016/j.jvs.2018.04.015. Epub 2018 May 24.